Skip to main content
13 April 2021
Last updated:
Tuesday 13 April 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

New board member at Elicera Therapeutics

Wednesday 31 March 2021
Company
Elicera Therapeutics AB
Appointee Name
Karin 
Hoogendoorn
Country

Sweden

Elicera Therapeutics AB has appointed the advanced therapy specialist Karin Hoogendoorn to its board of directors to help oversee development of the Swedish company’s CAR T and oncolytic virus therapies for cancer. Dr Hoogendoorn is currently senior director of chemistry, manufacturing and control (CMC) at the gene therapy company uniQure NV. Before that, she was head of preclinical services for cell and gene therapies at Lonza. She holds a master of science degree in biology and bio-pharmaceutical sciences from Leiden University, the Netherlands.

Elicera Therapeutics announced the appointment on 22 March 2021.

Copyright 2021 Evernow Publishing Ltd

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

René Hoet becomes CSO at Montis Biosciences
Wednesday March 31 2021
Pan Cancer T makes board appointments
Wednesday March 31 2021
Björn Englund appointed CEO at Opterion
Wednesday March 31 2021
Sven Zimmermann joins Inotrem
Wednesday March 31 2021
New director at Mission Therapeutics
Wednesday March 31 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.